Please login to the form below

Not currently logged in
Email:
Password:

antifungal

This page shows the latest antifungal news and features for those working in and with pharma, biotech and healthcare.

Shionogi and F2G partner to develop antifungal treatment olorofim

Shionogi and F2G partner to develop antifungal treatment olorofim

The deal, worth up to $480m, involves the first novel antifungal treatment developed in the last 20 years. ... Shionogi and F2G have partnered to develop and commercialise the new antifungal agent olorofim – formerly F901318 – for invasive fungal

Latest news

More from news
Approximately 4 fully matching, plus 31 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Basilea has granted an exclusive licence for isavuconazole (an iv and oral antifungal for invasive aspergillosis and mucomycosis) to Asahi Kasei in Japan.

  • Astellas: Ten years young Astellas: Ten years young

    class of OAB treatments to emerge in over 30 years, the antifungal Mycamine (micafungin) and the anti-infective Dificlir - the first new treatment in 50 years for clostridium difficile or c.

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    109. Astellas / Vical. Licence and collaboration. Preclinical antifungal ASP2397. 100.

  • Pharma deals during October 2013 Pharma deals during October 2013

    This proved to be the case with Dow Pharmaceutical Sciences, which had undertaken development work for Anacor on the topical antifungal tavaborole for the treatment of onychomycosis under a 2004 master

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • AstraZeneca’s John Rex joins UK biotech F2G AstraZeneca’s John Rex joins UK biotech F2G

    We are delighted that he is now able to increase his commitment to the company as we progress our new class of antifungal agents into our next clinical trials.”. ... In his new role Rex will be tasked with helping move F2G's first-in-class antifungal

  • F2G appoints chief financial officer F2G appoints chief financial officer

    Schmid brings over two decades of financial management experience to the antifungal drug discovery and development company, with particular expertise in mergers and acquisitions, licensing and public and private market transactions.

  • Cidara Therapeutics makes senior appointments Cidara Therapeutics makes senior appointments

    Balkovec has helped bring more than a dozen development candidates into clinical development, including the first approved echinocandin antifungal drug Cancidas (caspofungin), which he is additionally co-inventor of.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....